mannitol

Brand: Osmitrol

Prototype Drug
Drug Class: osmotic diuretic
Drug Family: diuretic
Subclass: polyol osmotic agent
Organ Systems: renalcns

Mechanism of Action

Freely filtered but not reabsorbed; increases tubular osmolarity preventing water reabsorption; draws water from tissues into intravascular space reducing cerebral edema.

proximal tubule osmotic retention (prevents reabsorption)

Indications

  • cerebral edema (increased ICP)
  • oliguric renal failure (flush)
  • acute hemolytic transfusion reaction (forced diuresis)
  • rhabdomyolysis (forced diuresis)

Contraindications

  • anuria
  • severe dehydration
  • pulmonary edema
  • active intracranial bleeding

Adverse Effects

Common

  • electrolyte disturbances
  • dehydration
  • increased intravascular volume (initial)
  • headache

Serious

  • severe hypovolemia
  • acute pulmonary edema (from initial volume expansion)
  • renal tubular damage (high doses)

Pharmacokinetics (ADME)

Absorption IV only
Distribution intravascular initially then CSF distribution
Metabolism not metabolized
Excretion renal unchanged
Half-life not applicable
Onset immediate IV
Peak immediate
Duration minutes to hours
Protein Binding low
Vd extracellular

Drug Interactions

Drug / Agent Mechanism Severity
loop diuretics additive diuresis; risk of severe dehydration moderate

Nursing Considerations

  1. Monitor serum osmolality (osmol gap target <320 mOsm/kg) and electrolytes
  2. Assess urine output: minimum 30-50 mL/hr during therapy
  3. Infuse via filter (crystallizes at low temperatures)
  4. Monitor ICP if placed for cerebral edema
  5. Avoid in patients with CHF (volume expansion worsens)

Clinical Pearls

  • Initial volume expansion (draws water from cells) then sustained diuresis
  • ICP reduction: draws water from brain tissue reducing cerebral edema; onset 15-30 minutes

Safety Profile

Pregnancy use-with-caution
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required